Physician profile
Xinhe Wei
NPI 1225871577
$8,082.88
in general payments reported to CMS, 2019-2025
59 companies · $7,260 in 2025
The $7,260 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $823 · 2025: $7,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,043 · Long Term Medical Supply Or Device Loan: $698 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,043.00 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $341.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,055.20 | 2024-2025 | |
| Aop Health US, LLC | $793.14 | 2025 | Rapiblyk |
| Janssen Biotech, INC. | $446.14 | 2024-2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $438.52 | 2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $437.90 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $363.81 | 2025 | Opdivo, Opdualag, Camzyos |
| Merck Sharp & Dohme LLC | $295.84 | 2024-2025 | Keytruda, Winrevair, Welireg |
| Seagen INC. | $276.98 | 2025 | |
| Eisai INC. | $241.19 | 2024-2025 | |
| Daiichi Sankyo INC. | $223.63 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Genentech USA, INC. | $199.22 | 2024-2025 | Polivy, Phesgo, Itovebi |
| Bayer Healthcare Pharmaceuticals INC. | $193.86 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $192.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.68 | 2024-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $151.39 | 2024-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.54 | 2025 | |
| Karyopharm Therapeutics INC. | $120.85 | 2024-2025 | Xpovio |
| Exelixis INC. | $119.17 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $106.68 | 2024-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.85 | 2024-2025 | Gilotrif, Jardiance |
| Coherus Oncology, INC. | $100.73 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $94.37 | 2025 | Monoferric |
| Geron Corporation | $91.53 | 2025 | Rytelo |
| Sobi, INC | $91.08 | 2024-2025 | |
| Puma Biotechnology, INC. | $88.82 | 2024-2025 | |
| Stemline Therapeutics INC. | $88.40 | 2024-2025 | Orserdu, Elzonris |
| Glaxosmithkline, LLC. | $87.48 | 2024-2025 | Ojjaara, Blenrep |
| Alexion Pharmaceuticals, INC. | $85.98 | 2024-2025 | Ultomiris |
| Emd Serono, INC. | $84.32 | 2024-2025 | |
| Genmab U.S., INC. | $84.16 | 2025 | Epkinly |
| Csl Behring | $81.64 | 2024-2025 | Idelvion, Afstyla |
| Array Biopharma INC | $71.55 | 2025 | Braftovi, Lorbrena, Mektovi |
| Celgene Corporation | $68.65 | 2025 | Opdivo |
| Syndax Pharmaceuticals, INC. | $65.79 | 2025 | |
| Iovance Biotherapeutics, INC. | $63.79 | 2025 | Amtagvi |
| Pfizer INC. | $54.93 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $49.98 | 2025 | Somatuline Depot, Onivyde |
| Ge Healthcare | $49.07 | 2025 | |
| Pharmaessentia USA Corporation | $48.15 | 2025 | Besremi |
| Caris Mpi, INC. | $44.32 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $43.70 | 2025 | |
| Tersera Therapeutics LLC | $37.50 | 2024 | Zoladex |
| Blueprint Medicines Corporation | $35.17 | 2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $31.22 | 2025 | |
| Astellas Pharma US INC | $29.06 | 2025 | Xtandi |
| Taiho Oncology, INC. | $27.37 | 2025 | |
| Immunocore Limited | $27.14 | 2024 | Kimmtrak |
| Gilead Sciences, INC. | $26.79 | 2025 | Trodelvy |
| Alnylam Pharmaceuticals INC. | $26.45 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $25.54 | 2025 | |
| Accord Healthcare, INC. | $24.93 | 2025 | |
| Lilly USA, LLC | $24.19 | 2025 | Jaypirca, Verzenio |
| Rigel Pharmaceuticals, INC. | $23.50 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Liquidia Technologies, INC. | $22.78 | 2025 | Yutrepia |
| Beone Medicines USA, INC. | $22.32 | 2025 | Tevimbra |
| Cumberland Pharmaceuticals, INC. | $20.66 | 2025 | Sancuso |
| Servier Pharmaceuticals LLC | $17.56 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.77 | 2024 | Pyrukynd |
| Bridgebio Pharma, INC. | $13.58 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xinhe Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.